Metals in medicine

Alternative Therapies in Health and Medicine

Volumn 11, Issue 4, 2005, Pages 18-25

  Nash, Robert A ^a  

^a Clinical Metal Toxicology ^*

Author keywords

[No Author keywords available]

Indexed keywords

CADMIUM; LEAD; MERCURY; THIOMERSAL;

AGING; CHELATION THERAPY; CLINICAL FEATURE; ENVIRONMENTAL FACTOR; HEALTH CARE ORGANIZATION; HUMAN; INDUSTRIALIZATION; METAL METABOLISM; PEER REVIEW; REVIEW; UNITED STATES; VASCULAR DISEASE;

CHELATING AGENTS; CHELATION THERAPY; ENVIRONMENTAL EXPOSURE; HAZARDOUS SUBSTANCES; HEALTH STATUS; HUMANS; LEAD POISONING; MERCURY POISONING; METALS, HEAVY; UNITED STATES; VASCULAR DISEASES;

EID: 22544440584     PISSN: 10786791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Crossing The Quality Chasm, A New Health System for the 21st Century. National Academy Press; Washington, DC: 2001.
2. Hyman M. Paradigm shift: the end of "normal science" in medicine understanding function in nutrition, health, and disease. Altern Ther Health Med. 2004;10(5):10-5, 90-94.
3. Gordon JS. The White House Commission on Complementary and Alternative Medicine Policy and the future of healthcare. Altern Ther Health Med. 2004;10(5):20-23.
4. Null G, Dean C, Feldman M, Rasio D. Death by Medicine. Nutrition Institute of America, Inc. November 2003. Available at: http://www.garynull.com/ -documents/iatrogenic/deathbymedicine/DeathByMedicinel.htm. Accessed May 2005.
5. Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med. 1993;328(4):246-252.
6. Eisenberg DM. Advising patients who seek alternative medical therapies. Ann Intern Med. 1997;127(1):61-69.
7. Available at: http://www.infoworld.com/article/05/05/13/ HNboomershealth_1.html. Accessed June 2005.
8. Krochmal P, Riley TA. Increased health care costs associated with ED overcrowding. Am J Emerg Med. 1994;12(3):265-266.
9. Hagland MM. Top developments in health care: a watershed year. Hospitals. 1991;65(24):26-29.
10. Halstead B, Rozema T. The Scientific Basis of EDTA Chelation Therapy. 2nd edition. TRC Pub; Landrum, SC: 1997, pg 5.
11. Rubin M, Gignac S, Bessman SP, Belknap EL Enhancement of Lead Excretion in Humans by Disodium Calcium Ethylenediamine Tetraacetate. Science 1953, 117 (659).
12. Rubin M, Pachtman E, Aldridge M, et al. The metabolism of parenteral iron chelates. Biochem Med. 1970;3(4):271-88.
13. Cranton E. A Textbook on EDTA Chelation Therapy. 2nd edition, 2001;ch 32:404-461
14. Boyle AJ, Clarke NE, Mosher RE, McCann DS. Chelation therapy in circulatory and sclerosing diseases. Fed Proc. 1961;20(3) Pt 2:243-52.
15. Kitchell JR, Meltzer LE, Seven MJ. Potential uses of chelation methods in the treatment of cardiovascular diseases. Prog Cardiovasc Dis. 1961;3:338-349.
16. Fuster V. The Vulnerable Atherosclerotic Plaque. Futura Pub., Armonk, NY: 1999.
17. Kolata G. New Studies Question Value of Opening Arteries. New York Times. 2004.
18. Holmes AS, Blaxill MF, Haley BE. Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol. 2003;22(4):277-285.
19. Heavy Metals in the Environment, editor, B. Sarkar, Marcel Dekker,NYC,NY,2003;ch12;410.
20. Clarkson TW, Magos L, Myers GJ. The toxicology of mercury-current exposures and clinical manifestations. N Engl J Med. 2003;349(18):1731-1737.
21. Bradstreet J. A Case-Control Study of Mercury Burden in Children with Autistic Spectrum Disorders. J of Amer Phys and Surg. 2003;8:76-79.
22. Waly M, Olteanu H, Banerjee R, et al. Activation of methionine synthase by insulin-like growth factor-1 and dopamine: a target for neurodevelopmental toxins and thimerosal. Mol Psychiatry. 2004;9(4):358-370.
23. Godfrey ME, Wojcik DP, Krone CA. Apolipoprotein E genotyping as a potential biomarker for mercury neurotoxicity. J Alzheimers Dis. 2003;5(3):189-195.
24. Lindh U, Hudecek R, Danersund A, Eriksson S, Lindvall A. Removal of dental amalgam and other metal alloys supported by antioxidant therapy alleviates symptoms and improves quality of life in patients with amalgam-associated ill health. Neuro Endocrinol Lett. 2002;23(5-6):459-482.
25. Available at: http://abcmt.com. Accessed June 2005.
26. Frustaci A, Magnavita N, Chimenti C, et al. Marked elevation of myocardial trace elements in idiopathic dilated cardiomyopathy compared with secondary cardiac dysfunction. J Am Coll Cardiol. 1999;33(6):1578-1583.
27. Lin JL, Lin-Tan DT, Hsu KH, Yu CC. Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med. 2003;348(4):277-286.
28. Navas-Acien A, Selvin E, Sharrett AR, et al. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation. 2004;109(25):3196- 3201. Epub 2004 Jun 7.
29. Impact of Mercury on Human Health and the Environment, two day symposium, Dept of Environmental Health Sciences, Tulane Univ School of Public Health with the Centers for Disease Control.Sep23,24,2004.
30. Hyman MH. The impact of mercury on human health and the environment. Altern Ther Health Med. 2004;10(6):70-75.
31. Erratum in: Altern Ther Health Med. 2005;11(1):19.
32. Haley B. Question and answer period. Impact of Mercury on Human Health and the Environment. Tulane University. September 23, 2004.
33. Jaffe RM. Toxic Metal Update. ICIM meeting, Atlanta, GA, Oct 6-10, 2004.
34. Haley, B. Chair, Dept of Biochemistry, U of KY, personal communication and lectures
35. Selevan SG, Rice DC, Hogan K A, et al. Blood lead concentration and delayed puberty in girls. N Engl J Med. 2003;348(16):1527-1536.
36. Nash D, Magder L, Lustberg M, et al. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA. 2003;289(12):1523-1532.
37. Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med. 2002;162(21):2443-2449.
38. Available at: http://www.universiyhealth.net/UICVideoInfo.html (click on the first video excerpt). Accessed June 2005.
39. Available at: www.epa.gov/ost/fish/. Accessed June 2005.
40. Available at: www.cseindia.org/dte-supplement/global-warming.htm. Accessed June 2005.
41. Nash R. Mercury in Medicine. Available at: http://ncof.com/ AaeJournal5aa_ejournal guest.htm., pg 4 of 6
42. Reuters, 11:39 a.m.ET Aug. 9, 2004, Britain removes mercury from baby vaccine.
43. Pendergrass JC, Haley BE. Inhibition of brain tubulin-guanosine 5′-triphosphate interactions by mercury: similarity to observations in Alzheimer's diseased brain. Met Ions Biol Syst. 1997;34:461-78
44. Pendergrass JC, Haley BE, Vimy MJ, Winfield SA, Lorscheider FL. Mercury vapor inhalation inhibits binding of GTP to tubulin in rat brain: similarity to a molecular lesion in Alzheimer's diseased brain. Neurotoxicology. 1997;18(2):315-24.
45. Dossey L. The right man syndrome: skepticism and alternative medicine. Altern Ther Health Med. 1998;4(3):12-9, 108-114.
46. Available at: http://www.amalgam.org/. Accessed June 2005.
47. Available at: http://www.internat.naturvardsverket.se/. Accessed June 2005.
48. Lindvall, Anders. Foundation for Metal Biology, Uppsala, Sweden, personal communication given at the Tulane Seminar, Sep 23, 24, 2004, Impact of Mercury on Human Health and the Environment
49. Lindh U, Carlmark B, Gronquist SO, Lindvall A. Metal exposure from amalgam alters the distribution of trace elements in blood cells and plasma. Clin Chem Lab Med. 2001;39(2):134-142.